Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper
Open Access
- 25 February 2020
- journal article
- review article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (4) , 762-775
Abstract
The incidence of acute myeloid leukemia (AML) increases with age. Intensive induction chemotherapy containing cytarabine and an anthracycline has been part of the upfront and salvage treatment of AML for decades. Anthracyclines are associated with a significant risk of cardiotoxicity (especially anthracycline-related left ventricular dysfunction [ARLVD]). In the older adult population, the higher prevalence of cardiac comorbidities and risk factors may further increase the risk of ARLVD. In this article of the Young International Society of Geriatric Oncology group, we review the prevalence of ARLVD in patients with AML and factors predisposing to ARLVD, focusing on older adults when possible. In addition, we review the assessment of cardiac function and management of ARLVD during and after treatment. It is worth noting that only a minority of clinical trials focus on alternative treatment strategies in patients with mildly declined left ventricular ejection fraction or at a high risk for ARLVD. The limited evidence for preventive strategies to ameliorate ARLVD and alternative strategies to anthracycline use in the setting of cardiac comorbidities are discussed. Based on extrapolation of findings from younger adults and nonrandomized trials, we recommend a comprehensive baseline evaluation of cardiac function by imaging, cardiac risk factors, and symptoms to risk stratify for ARLVD. Anthracyclines remain an appropriate choice for induction although careful risk-stratification based on cardiac disease, risk factors, and predicted chemotherapy-response are warranted. In case of declined left ventricular ejection fraction, alternative strategies should be considered.Keywords
This publication has 144 references indexed in Scilit:
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- The development of congestive heart failure and ventricular tachycardia after first exposure to idarubicin in a patient with acute myeloid leukaemiaBritish Journal of Clinical Pharmacology, 2010
- Anthracycline-Induced CardiomyopathyJACC, 2010
- The Burden of Cardiovascular Disease in the Elderly: Morbidity, Mortality, and CostsClinics in Geriatric Medicine, 2009
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to AnthracyclinesJournal of Clinical Oncology, 2004
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJACC, 2000